Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Merck and Schering-Plough announced a definitive merger agreement valued at $41.1 billion structured as a reverse merger to preserve joint venture rights to…
The deal will result in billions in annual savings for the merged entity, with expected annual cost reductions of $3.5 billion and expanded geographic reach…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Merck acquired Schering-Plough in a $41.1 billion reverse merger, gaining a diversified portfolio including Remicade, Nasonex, and the Vytorin/Zetia cholesterol franchise, creating the second-largest pharmaceutical company globally at the time.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Schering-Plough Corp. (this deal) | 2009 | $41.1B | 69 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2009 deals · Merck & Co. Inc. deals · Cardiovascular deals